Page 1

11 November 2021 Syncona Limited Interim Results for the six months ended 30 September 2021 Continued focus on hands - on engagement with a maturing portfolio with key milestones ahead Key highlights Net assets of £ 1,152.8 million ( 31 March 2021 : £ 1,300.3 million ) , or 171.7p¹ per share ( 31 March 2021 : 193.8p per share ) , a NAV total return of ( 11.4 ) per cent² driven predominantly by the decline in share prices of two of our listed holdings , Freeline Therapeutics ( Freeline ) and Achilles Therapeutics ( Achilles ) : Freeline experienced operational challenges as a result of the COVID 19 pandemic ; these have now been addressed and the business re initiated its clinical studies Achilles ' share price has been impacted by market sentiment towards cell and gene therapies ; Syncona's view is that the business is performing well and executing in line with its expected timelines Continued operational progress across the portfolio , with decisive actions taken by a number of our portfolio companies during the period : o Syncona CIO and Freeline Chair , Chris Hollowood closely engaged with the Freeline Board as it updated its executive leadership team Syncona CEO , Martin Murphy , took up the role of Chair of Autolus Therapeutics ( Autolus ) , working with its board to ensure the company focused on the delivery of the AUTO1 ( obe - cel ) pivotal study Positive clinical progress across five clinical stage companies : Autolus : further encouraging durability data from its lead therapeutic candidate AUTO1 for adult acute lymphoblastic leukaemia ( ALL ) Gyroscope Therapeutics ( Gyroscope ) : additional positive interim data in its Phase I / II FOCUS trial for the treatment of advanced dry age related macular degeneration ( AMD ) Freeline : dosed second patient in its second clinical programme for Fabry disease and post period end announced encouraging data from the patient ; enrolment begun in run - in study for its Phase I / II dose confirmation study for Haemophilia B Achilles : continued to make progress in ongoing Phase I / Ila studies in non - small cell lung cancer ( NSCLC ) and melanoma , enrolling patients in a higher dose process Anaveon : dosed its first patient in a Phase I / II study of ANV419 , a selective interleukin - 2 ( IL - 2 ) agonist with the potential to target cancer ; several patients have now been dosed in the study Next generation of companies poised to enter the clinic : 1 Fully diluted , please refer to note 9 in the condensed consolidated financial statements 2 Alternative performance measure , please refer to glossary